Validation of a Comprehensive Next-generation Sequencing Liquid Biopsy Assay for Clinical Diagnostics and Clinical Trial Applications Read more about Validation of a Comprehensive Next-generation Sequencing Liquid Biopsy Assay for Clinical Diagnostics and Clinical Trial Applications
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer Read more about Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression Read more about Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer Read more about Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay Read more about Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
Outcomes in oncogenic-addicted advanced NSClC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay Read more about Outcomes in oncogenic-addicted advanced NSClC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
Circulating tumor DNA genomics reveal potential mechanisms of resistance to BRAF-targeted therapies in patients with BRAF-mutant metastatic non–small cell lung cancer Read more about Circulating tumor DNA genomics reveal potential mechanisms of resistance to BRAF-targeted therapies in patients with BRAF-mutant metastatic non–small cell lung cancer
Liquid biopsies for residual disease and recurrence Read more about Liquid biopsies for residual disease and recurrence